In the first installment of this CME Outfitters Snack series, expert faculty will guide learners through an overview of challenges and recent developments in immunotherapy, as well as guideline recommendations on their implementation in practice. Faculty will also detail strategies designed to increase implementation of best practices in genetic and biomarker testing for cancer immunotherapy.
Dr. Schalper trained as cell/molecular biologist and surgical pathologist. His professional experience includes clinical molecular diagnostics and development of cancer biomarkers. His laboratory focuses on understanding dominant immune evasion pathways in human solid tumors and deciphering the structural/functional determinants of the tumor immune microenvironment in lung cancer. Dr. Schalper is also the Director of the Translational Immuno-oncology Laboratory at the Yale Cancer Center where he leads the standardized analysis of biomarkers in clinical trials using advanced cell/tissue analysis platforms.
Dr. Banu Arun is Professor in Department of Breast Medical Oncology, Co-Medical Director of the Clinical Cancer Genetics Program, and Section Chief Breast Genetics, Prevention and Screening at the University of Texas MD Anderson Cancer Center. Her research focuses on identifying risk biomarkers for breast cancer and prevention and characterizing risk factors in a cohort of high-risk women with hereditary gene mutations (BRCA and others) as well as assessing breast cancer biology in these patients. Dr. Arun has served as the Principal Investigator on several clinical trials evaluating agents such as letrozole, imatinib, gemcitabine, R115777, and PARP inhibitors for metastatic breast cancer and celecoxib, atorvastatin, dasatinib, and Tamoxifen Gel in short-term breast cancer prevention trials. Her research also includes outreach and education, as well as cascade genetic testing of family members.
Given her national and international expertise, she has served on several committees, including The American Society of Clinical Oncology (ASCO) Prevention committee ASCO Prevention Education Committee and currently serves as the Co-Chair for the Southwest Oncology Group (SWOG) Prevention and Epidemiology Committee and member of the NCCN Breast Cancer Risk Reduction Guideline Committee as well as the NCCN Breast Hereditary Genetics Guideline Committee, member of the ASCO Germline Genetic Testing Guideline Panel, and member of the National Cancer Institute (NCI) Cancer Prevention Steering Committee. She served as grant reviewer for Susan Komen and NCI P01 and reviewed for journals including the Journal of Clinical Oncology, Cancer, British Medical Journal, Cancer Prevention and Epidemiology, amongst others. She has more than 200 peer-reviewed publications and received research grants from the NCI, DoD, Susan Komen Foundation, and CPRIT.
She was featured in Forbes (December 2017) as one of the top 30 Breast Medical Oncologists in the United States. She has received FASCO award recognition in 2020 from the American Society of Clinical Oncology and is the recipient of the ASCO–American Cancer Society Award 2021.
In the second installment of this CME Outfitters Snack series, expert faculty will discuss strategies for providing high-quality genetic counseling and services for underserved patients with cancer, including leveraging health technology (e.g. telehealth), utilizing a collaborative/interprofessional approach to genetic counseling, and implementing a workable process for patient identification and triage.
Dr. Ioffe is a gynecologic oncologist in Southern California. She completed her training in gynecologic oncology at Washington University/Barnes-Jewish Hospital in St. Louis. Her practice focus has included improving care of women afflicted with gynecologic malignancies in the underserved San Bernardino and Riverside counties.
Her academic interest has focused on establishing a fellowship training program in gynecologic oncology in those underserved counties.
Her research interests include: impact of genetic and molecular alterations on treatment and outcome of ovarian cancer and improving genetic testing rates in gynecologic oncology patients.
Dr. Banu Arun is Professor in Department of Breast Medical Oncology, Co-Medical Director of the Clinical Cancer Genetics Program, and Section Chief Breast Genetics, Prevention and Screening at the University of Texas MD Anderson Cancer Center. Her research focuses on identifying risk biomarkers for breast cancer and prevention and characterizing risk factors in a cohort of high-risk women with hereditary gene mutations (BRCA and others) as well as assessing breast cancer biology in these patients. Dr. Arun has served as the Principal Investigator on several clinical trials evaluating agents such as letrozole, imatinib, gemcitabine, R115777, and PARP inhibitors for metastatic breast cancer and celecoxib, atorvastatin, dasatinib, and Tamoxifen Gel in short-term breast cancer prevention trials. Her research also includes outreach and education, as well as cascade genetic testing of family members.
Given her national and international expertise, she has served on several committees, including The American Society of Clinical Oncology (ASCO) Prevention committee ASCO Prevention Education Committee and currently serves as the Co-Chair for the Southwest Oncology Group (SWOG) Prevention and Epidemiology Committee and member of the NCCN Breast Cancer Risk Reduction Guideline Committee as well as the NCCN Breast Hereditary Genetics Guideline Committee, member of the ASCO Germline Genetic Testing Guideline Panel, and member of the National Cancer Institute (NCI) Cancer Prevention Steering Committee. She served as grant reviewer for Susan Komen and NCI P01 and reviewed for journals including the Journal of Clinical Oncology, Cancer, British Medical Journal, Cancer Prevention and Epidemiology, amongst others. She has more than 200 peer-reviewed publications and received research grants from the NCI, DoD, Susan Komen Foundation, and CPRIT.
She was featured in Forbes (December 2017) as one of the top 30 Breast Medical Oncologists in the United States. She has received FASCO award recognition in 2020 from the American Society of Clinical Oncology and is the recipient of the ASCO–American Cancer Society Award 2021.
Expert Dr. Anita Afzali will utilize case-based learning to illustrate the common features and pathophysiologic mechanisms underlying these two inflammatory disorders. Faculty will translate clinical data to help clinicians to select optimal treatments aimed at improving outcomes for patients impacted by PsO and IBD.
Anita Afzali, MD, MPH, MHCM, is a Professor of Clinical Medicine and a gastroenterologist that specializes in Inflammatory Bowel Disease (IBD). She has recently transitioned to the University of Cincinnati after successfully building the first standalone multidisciplinary IBD Center and serving as the Medical Director at The Ohio State University Wexner Medical Center for five years. Dr. Afzali is now the Executive Vice Chair of the Department of Internal Medicine at the University of Cincinnati and Associate Chief Medical Officer of UC Health Systems and Cincinnati Children’s Hospital. She received her medical degree and completed both an Internal Medicine residency and Gastroenterology fellowship at the University of Washington in Seattle, WA. While in fellowship, Dr. Afzali worked in outcomes research and epidemiology and graduated with a Master’s in Public Health. She recently obtained an additional Master’s in Health Care Management for physician executive leadership and business administration from Harvard University. Her areas of research interest include clinical outcomes and clinical trials for investigative therapies and diagnostics in IBD. She is a healthcare redesign leader with interests in clinical operations and transformative medical care delivery. Dr. Afzali has extensive peer-reviewed publications and is a clinical trialist in over 20 investigative drug and diagnostic trials. She is also an invited lecturer on national and international programs and serves on several international advisory boards and scientific committees. Dr. Afzali is the incoming Chair of the American College of Gastroenterology (ACG) Educational Affairs Committee and the incoming Chair of the World Gastroenterology Organization (WGO) Publications Committee, as well as Co-Editor of the WGO quarterly global newsletters.
In the third installment of this CME Outfitters Snack series, expert faculty will discuss the role of predictive biomarkers in guiding clinical decision-making, practical guidance for testing requirements and recommendations, and shared decision-making. Faculty will also present illustrative examples of utilizing testing to guide therapy.
Dr. Coleman completed his Obstetrics & Gynecology residency at Northwestern University Medical Center in Chicago, Illinois, and completed his fellowship at The University of Texas MD Anderson Cancer Center in 1993. Prior to joining the M.D. Anderson faculty in 2004, he served as Vice-Chairman, Department of Obstetrics and Gynecology at the University of Texas, Southwestern Medical Center in Dallas. At M.D. Anderson, Dr. Coleman was a Professor and served as the Executive Director for Cancer Network Research, holding the Ann Rife Cox Chair in Gynecology. In March 2020, he joined US Oncology Research (USOR) as their Chief Scientific Officer and currently serves as Chief Medical Officer for Sarah Cannon Research Institute (SCRI), a joint venture research organization between USOR and SCRI.
Dr. Coleman has authored or coauthored over 700 scientific publications, including over 410 peer-reviewed articles, along with numerous book chapters, monographs, invited articles, and textbooks. In 2019, he received the 2019 APGO-CREOG award for Excellence in Teaching. He is a co-Director for GOG-Partners and serves on the Board of Directors for GOG-Foundation, Inc. He is the immediate Past-President of the International Gynecologic Cancer Society (IGCS) and was recently inducted into MJH Life Sciences 2020 class of “Giants in Cancer Care.”
Dr. Banu Arun is Professor in Department of Breast Medical Oncology, Co-Medical Director of the Clinical Cancer Genetics Program, and Section Chief Breast Genetics, Prevention and Screening at the University of Texas MD Anderson Cancer Center. Her research focuses on identifying risk biomarkers for breast cancer and prevention and characterizing risk factors in a cohort of high-risk women with hereditary gene mutations (BRCA and others) as well as assessing breast cancer biology in these patients. Dr. Arun has served as the Principal Investigator on several clinical trials evaluating agents such as letrozole, imatinib, gemcitabine, R115777, and PARP inhibitors for metastatic breast cancer and celecoxib, atorvastatin, dasatinib, and Tamoxifen Gel in short-term breast cancer prevention trials. Her research also includes outreach and education, as well as cascade genetic testing of family members.
Given her national and international expertise, she has served on several committees, including The American Society of Clinical Oncology (ASCO) Prevention committee ASCO Prevention Education Committee and currently serves as the Co-Chair for the Southwest Oncology Group (SWOG) Prevention and Epidemiology Committee and member of the NCCN Breast Cancer Risk Reduction Guideline Committee as well as the NCCN Breast Hereditary Genetics Guideline Committee, member of the ASCO Germline Genetic Testing Guideline Panel, and member of the National Cancer Institute (NCI) Cancer Prevention Steering Committee. She served as grant reviewer for Susan Komen and NCI P01 and reviewed for journals including the Journal of Clinical Oncology, Cancer, British Medical Journal, Cancer Prevention and Epidemiology, amongst others. She has more than 200 peer-reviewed publications and received research grants from the NCI, DoD, Susan Komen Foundation, and CPRIT.
She was featured in Forbes (December 2017) as one of the top 30 Breast Medical Oncologists in the United States. She has received FASCO award recognition in 2020 from the American Society of Clinical Oncology and is the recipient of the ASCO–American Cancer Society Award 2021.
Managing type 2 diabetes (T2D) is more than lowering blood sugar. In this short whiteboard animation, you’ll see the connection between T2D and cardiovascular disease (CVD), which includes heart attack and stroke. The good news is that a combination of balanced nutrition, regular exercise, and newer medications for T2D can both lower blood sugar and lower your risk of CVD.
Join Dr. Isaiah Cochran and Daniel Garza for an inside look at fact vs. fiction when it comes to HIV prevention and as they discuss available options for pre-exposure prophylaxis (PrEP).